Navigation Links
Oncolytics Biotech Inc. Announces Issuance of 27th U.S. Patent
Date:5/20/2008

CALGARY, May 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted U.S. Patent 7,374,752 entitled "Reovirus for the Treatment of Cellular Proliferative Disorders." The claims cover pharmaceutical compositions which comprise various recombinant reoviruses.

"This patent provides the Company with additional patent protection for reovirus compositions in the United States," said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This news release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company's belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company's expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in the Company's business and technologies, involve known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals a
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... FALLS, N.Y., Jan. 15, 2014   Niagara Thermal ... been selected by Buffalo BioBlower Technologies LLC ("B3") as ... SBIR Phase 2 award from the Army Corps of ... system that kills all biological contaminants and destroys VOCs ...
(Date:1/15/2014)... and SAN JOSE, California , January ... company developing antibody-drug conjugates for cancer, today announced the appointment ... Directors. Dr Reynolds has over 20 years, development experience gained ... at Seattle Genetics. "I am delighted to welcome ...
(Date:1/15/2014)... January 15, 2014 A study has been ... the Formula 1 track could help to tackle the problem ... (MAT), Stowhealth (a GP surgery based in Stowmarket) and academics ... Simplyhealth. Telemetry technology, which is inspired by equipment ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains ... these latent viruses is the Epstein Barr Virus (EBV), and ... (RA) is a chronic inflammatory disease that destroys the body’s ... RA patients have high concentrations of EBV DNA in their ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... Md., Jan. 26 Novavax, Inc. (Nasdaq:, NVAX ... Good Manufacturing,Practice ("GMP") Pilot Plant to manufacture pandemic and ... 1,000 liter scale are,installed and ready for operations supporting ... project was initiated in December 2007. The facility ...
... Inc., a leading provider of enterprise-wide software and ... announced it has entered into a partner referral ... Alcoholism and Substance Abuse Providers (ASAP) for Netsmart ... learning management solution. ASAP is a not-for-profit membership ...
... Battelle for submission of proposals to U.S. Government ... Medical Corporation (OTC Bulletin Board: CONX), a worldwide ... announced a collaboration with Battelle, a Columbus, Ohio-based ... includes national security. Under the collaboration, Corgenix will ...
Cached Biology Technology:Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility 2Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility 3Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility 4Netsmart University Announces Partner Referral Agreement With New York Association of Alcohol and Substance Abuse Providers 2Netsmart University Announces Partner Referral Agreement With New York Association of Alcohol and Substance Abuse Providers 3Corgenix Signs Collaboration With Battelle 2Corgenix Signs Collaboration With Battelle 3
(Date:4/24/2014)... Ludwig-Maximilians-Universitaet (LMU) in Munich have identified the structural ... discriminate between viral and endogenous RNAs in living ... control of cellular metabolism and hijack cellular resources ... is dependent on viral RNA molecules that are ... viruses) and/or newly synthesized in the host cell, ...
(Date:4/24/2014)... State University and the University of North Carolina at ... could help identify arterial plaque that is at high ... stroke. , At issue is the plaque that builds ... plaque are deemed "vulnerable," meaning that they are more ... heart attack or stroke. , "Existing state-of-the-art technologies are ...
(Date:4/24/2014)... river turtle in North America, weighing in at up ... researchers from Florida and the University of Vermont have ... three. , Examining museum specimens and wild turtles, the ... , Once heavily hunted for turtle meat alligator ... in the 1960s the riverine populations have been ...
Breaking Biology News(10 mins):Viral infections: Identifying the tell-tale patterns 2Viral infections: Identifying the tell-tale patterns 3New ultrasound device may add in detecting risk for heart attack, stroke 2Two new US turtle species described 2Two new US turtle species described 3
... greater role in the disparity between the numbers of ... with the disease. A study by researchers at the ... the disparity was substantially reduced when comparing groups of ... environments. The results are published in the November 2008 ...
... RELEASE LEDs ... Chemical Society Researchers in Germany are describing a ... facial wrinkles. Their study, scheduled for the November 5 ... a bi-monthly journal, reports that high intensity visible light ...
... amyloid-b (Ab), builds up into fibrous plaques in the ... membrane microdomain to another to be cleaved, report Sakurai ... that Ab plaques are the direct cause of Alzheimer,s ... And working on this hypothesis, scientists are investigating just ...
Cached Biology News:Hypertension disparity linked to environment 2American Chemical Society Weekly PressPac Oct. 15, 2008 2American Chemical Society Weekly PressPac Oct. 15, 2008 3American Chemical Society Weekly PressPac Oct. 15, 2008 4American Chemical Society Weekly PressPac Oct. 15, 2008 5American Chemical Society Weekly PressPac Oct. 15, 2008 6American Chemical Society Weekly PressPac Oct. 15, 2008 7American Chemical Society Weekly PressPac Oct. 15, 2008 8
... Kit uses a simplified procedure and streamlines ... The kit is based on the three ... and sodium bisulfite where cytosine is converted ... innovative in-column desulphonation reaction eliminates several precipitation ...
... The DIGIVIEW line of digital x-ray ... radiation imaging device complete with 12 to ... area consists of a photodiode array sensor ... All models are available in low x-ray ...
Metamine is an autonomous data mining tool that extends the capabilities of conventional research teams. It is a proactive agent that searches for significant results buried within the GeNet data rep...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selecitivty and potential CNS-Side Effect liabilities of compo...
Biology Products: